Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab-Reference-Cited by-同舟云学术

Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab

Published:2023-04-27 Issue:7 Volume:28 Page:913-921
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Nakamura Kazutaka,Ishiyama Yudai^ORCID,Nemoto Yuki,Ishihara Hiroki,Tachibana Hidekazu,Fukuda Hironori,Shinmura Hiroaki,Hashimoto Yasunobu,Yoshida Kazuhiko,Iizuka Junpei,Ishida Hideki,Kondo Tsunenori,Takagi Toshio

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02341-x.pdf

Reference38 articles.

1. Tripathi A, Plimack ER (2018) Immunotherapy for urothelial carcinoma: current evidence and future directions. Curr Urol Rep 19(12):109. https://doi.org/10.1007/s11934-018-0851-7

2. Witjes JA, Bruins HM, Cathomas R et al (2021) European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79(1):82–104. https://doi.org/10.1016/j.eururo.2020.03.055

3. Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970–976. https://doi.org/10.1093/annonc/mdz127

4. Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683

5. Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124. https://doi.org/10.1093/jnci/dju124

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab;Japanese Journal of Clinical Oncology;2024-03-14

2. Prognostic Value of the Lung Immune Prognostic Index on Recurrence after Radical Surgery for High-Risk Renal Cell Carcinoma;Cancers;2024-02-14

3. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18

4. Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab;2023-11-08